Phenotypic Variability of 17q12 Microdeletion Syndrome - Three Cases and Review of Literature.

Chromosome 17q12 microdeletion syndrome is a contiguous gene deletion syndrome caused by an 1-2 Mb loss, characterized by multicystic dysplastic kidneys or other urinary system anomalies starting in utero, including autism or maturity-onset diabetes of the young in its postnatal phenotype. Here, we report on three cases (two prenatal and one postnatal) with distinct and novel clinical presentations as compared with a large number of reviewed patients, thus emphasizing the phenotypic variability of this syndrome and the consequent difficulties in genetic counselling. Prenatal hyperechogenic multicystic kidneys, as well as other urinary tract anomalies, should be considered a marker, therefore indicating the necessity of comprehensive genetic testing, and autism should also be acknowledged as a possible clinical presentation, postnatally.

INTRODUCTION

Chromosome 17q12 microdeletion syndrome (MIM 614527) is a contiguous gene deletion syndrome caused by a 1–2.5 Mb loss [1, 2, 3], with a widely variable phenotype ranging from prenatal multicystic dysplastic kidneys or other urinary system anomalies to postnatal pancreatic disfunction (maturity onset diabetes of the young type 5 – MODY5) in approx. 40% of patients, or neurodevelopmental disorder (mild to moderate intellectual disability, speech delay, autistic features, schizophrenia, rarely epilepsy) in approx. 50% of patients [1, 3]. Facial dysmorphisms (frontal bossing, malar flattening, micrognathia, retrognathia, downslanting palpebral fissures, depressed nasal bridge) have been described, as well as pancreatic atrophy, liver abnormalities, genital anomalies in both sexes or Mullerian dysplasia or aplasia in females, transient neonatal hypercalcemia, and neonatal cholestasis [1–2, 4,5,6,7]. The same genetic defect has been associated with Mayer-Rokitansky-Kuester-Hauser syndrome, suggesting the existence of a continuous spectrum of phenotypes associated with 17q12 microdeletion [5]. However, to date, no correlation between the deletion size and gene content and clinical phenotype has been established. Moreover, patients with similar phenotypes were reported, carrying mutations in HFN1B gene [1].

Deletion of 17q12 is incompletely penetrant and its expressivity is highly variable, ranging from severe anomalies, leading to kidney failure before birth, to mild or no problems at all. While 70% of deletions occur de novo, instances where the deletion was inherited from an asymptomatic parent have been reported [6].

The critical region at 17q12 is flanked by polymorphic segmental duplications and contains at least 15 genes, out of which HFN1B and LHX1 are hypothesized to be essential for renal function, neuropsychiatric conditions, and female genital anomalies [2, 8]. Many of the remaining genes, such as CCL and TBC1D, have multiple copies as normal population variants and are not likely to be dosage sensitive. Reciprocal duplications are associated with intellectual disability and epilepsy, though asymptomatic individuals have also been described [1].

While the overall prevalence of 17q12 deletion syndrome is unknown, a Danish study estimated its country prevalence as 1.6:1,000,000 [7]. Wan et al. (2019) [9] found that 4.2% of fetuses carried a 17q12 deletions spanning between 1.42–1.58 Mb in a cohort of 126 pregnancies with renal anomalies detected by ultrasound.

In this article, we present 3 new cases of 17q12 deletions and review a large number of the reports, covering 92 patients with this genetic anomaly. Patients were selected based on their renal disorder phenotype or, if asymptomatic and carrying the deletion, the presence of a renal phenotype in a first degree relative. Patients with a primary diagnosis of Mullerian dysplasia or aplasia, Mayer-Rokitansky-Kuester-Hauser syndrome or only MODY5 were not included in the current study. However, given the complexity and the wide variability of the phenotype, from asymptomatic to lethal, the genetic counseling is therefore difficult and conversations about the implications of 17q12 microdeletion must continue.

MATERIALS AND METHODS

Patient A was a 19-year-old gravida 1, referred for genetic testing at 24 weeks. She was selected due to a unilateral multicystic dysplastic kidney of the fetus, without other anomalies and with a normal fetal growth. The results of the biochemical screening for chromosomal aneuploidies were not available.

Patient B was a 26-year-old gravida 1, referred for genetic testing at 17 weeks. She was selected due to megabladder (defined as the sagittal dimension of the bladder (mm) greater than gestational age (weeks) plus 12), single umbilical artery, choroid plexus cyst, and possibly absent ductus arteriosus. First trimester biochemical screening results showed a high risk for chromosomal aneuploidies (1/56 for trisomy 21, 1/107 for trisomy 13, and 1/193 for trisomy 18; cutoff 1/250). In both cases, amniotic fluid was collected for analysis.

Patient C was a 7 year 5 months old boy, referred to genetic investigations following a diagnosis of autism spectrum disorder with developmental delay. He is the second child of healthy, nonconsanguineous parents born at 39 weeks, after a normal pregnancy, except for an ultrasound image of hydronephrosis in the right kidney at 22 weeks of gestation. With a birth weight of 2,850 g, a length of 52 cm, and an Apgar score of 7 due to some breathing difficulties, the patient had good postnatal adaptation. His developmental landmarks were delayed (he held his head at 7 months, sat at 12 months, walked at 1 year and 7 months, and pronounced first syllables at 1 year and 8 months, with his first words at 5 years). Hydronephrosis was surgically corrected at 12 months. He was diagnosed with autism spectrum disorder (ASD) at 3 years and started applied behavior analysis (ABA) therapy as well as speech therapy and cognitive stimulation at the age of 4. Currently, he attends his final year of kindergarten, with satisfactory results, though with socialization difficulties. The family history revealed the presence of a maternal cousin with cognitive delay and epilepsy. Clinical evaluation showed macrocephaly (occipitofrontal circumference 58 cm, +4.3 SD), dysmorphic facial features (deep set eyes, synophris, long philtrum, anteverted nostrils, posteriorely rotated ears, abnormal teeth, micrognathia); prominent occiput; joint hyperlaxity, single palmar crease, spindle-shaped fingers, clinodactily of the fifth finger; inverted nipples; small phallus and bilateral cryptorchidism; hirsutism; poor fine and gross motor skills, hypotonia, language and speech problems (poor language production, inability to understand complex orders, echolalia, polymorphic dyslalia); mild intellectual disability (IQ 60); social skills deficit with poor eye contact, difficulties in interaction with other persons, stereotyped behavior, low tolerance to frustration. An MRI investigation showed a mild bilateral frontal atrophy and a small frontobasal subarachnoidian cyst.

Genetic counselling of the patients was done by a clinical geneticist. Written informed consent on the use of their data for scientific purposes was given by the patients (A, B) or patient's legal guardian (C). Array-CGH was performed on an Agilent Technologies 60K platform according to the supplied protocol for patients A and B, while SNP array (Affymetrix) on a 750K platform was carried out for C patient. Following genetic analysis, pregnancies of patients A and B were terminated, without pursuing any further investigations.

Written informed consent on the use of their data for scientific purposes was given by all patients, in compliance with international and national regulations. Patient C was investigated within the frame of research project EEA RO-NO 6/2019, in accordance with the above regulations and approved by the institutional Ethics Committee, no. 33/Nov. 26, 2019.

RESULTS

The fetus of patient A carried a microdeletion with a minimal size of 1.35 Mb at 17q12, 34,817,422-36,168,104 (hg19), encompassing 18 genes: PIGW, ACACA, HNF1B, ZNHIT3, GGNBP2, DHRS11, LHX1, AATF, TADA2A, DUSP14, DDX52, MYO19, MRM1, MIR2909, SNORA90, C17ORF78, SYNRG, MIR378. The fetus of patient B exhibited a 1.31 Mb loss at 17q12, 34,851,537-36,168,104 (hg19), encompassing the same 18 genes. A conventional karyotype was also performed in both cases, showing normal chromosomal complements.

Patient C presented a 1.80 Mb deletion at 17q12 at 34,475,679-36,283,807 (hg19) including CCL3L3, CCL3L1, CCL4L2, TBC1D3C, TBC1D3G, TBC1D3H, PIGW, ACACA, HNF1B, ZNHIT3, GGNBP2, DHRS11, LHX1, AATF, TADA2A, DUSP14, DDX52, MYO19, MRM1, MIR2909. SNORA90, C17ORF78, SYNRG, MIR378.

In neither case was parental DNA available for further investigation.

DISCUSSION

While the number of reported prenatal cases of 17q12 microdeletion is increasing and its clinical description is continuously updated, the phenotypic variability of this syndrome and the difficulties it raises in genetic counselling invite a broader discussion regarding the molecular mechanisms underlying this condition and their correlation with clinical presentations. Decramer et al. (2017) [10] suggest that about 20% of prenatal hyperechogenic kidney cases are caused by 17q12 deletions, though O’Donnelly et al. (2014) [11] hypothesize it to be the second most common genetic anomaly in fetuses with abnormal ultrasound results and a normal karyotype, following 22q11.21 deletion, at a similar frequency with 16p13.11 deletion. 17q12 deletion is also among the ten most common microdeletions in children with unexplained neurodevelopmental disorders [12].

Our report describes three cases with prenatal urinary tract anomalies (multicystic dysplastic kidney, megabladder, and hydronephrosis, respectively); two of the pregnancies were subsequently terminated, while the third case had developmental delay and ASD. All our patients carry only one functional copy of four genes classified as pathogenic in OMIM: PIGW, ACACA, ZNHIT3, HNF1B, as well as the LHX1 gene. While the mechanism causing megabladder in the fetus of patient B cannot be traced unequivocally to 17q12 deletion, the presence of urinary tract abnormalities in the clinical phenotype of this syndrome suggests a plausible causal relationship.

As illustrated in Table 1, prenatal phenotypes associated with 17q12 microdeletion cover a large spectrum of ultrasound markers, from none to hyperechogenic, multicystic, or enlarged kidneys, absent unilateral kidney, and hydronephrosis. These markers can be detected at as early as 15 weeks of gestation [35], along with other findings (intestinal obstruction, congenital diaphragmatic hernia, lung anomalies, persistent left superior vena cava, poly- or oligohydramnios etc.). Two of our cases fall within the beginning of this spectrum, with single urinary tract abnormalities and with normal fetal growth. It is estimated that prenatal renal cysts are detected in more than half of the patients with post-natal kidney anomalies and that, regardless cyst detection in utero, most patients develop or increase their number in the first year of life [10]. Our reviewed cases include two sets of twins (P30–31, P44–45) carrying identical deletions. P30–31 twins exhibited similar prenatal phenotypes while progressing discordantly following birth, some patients presented prenatal kidney abnormalities which resolved after birth, while others did not show any anomaly upon prenatal ultrasound, but postnatal developmental delay and neuropsychiatric symptoms (Table 1). Moreover, the reviewed literature describes patients with mild phenotypes, who were diagnosed with 17q12 microdeletion syndrome only after having an affected pregnancy or due to other primary complains such as hypomagnesemia and subsequent investigations leading to renal disorder (e.g. P92 – Table 1). Difficulties in reviewing medical records and attaining an accurate medical history, particularly in adult and elder patients, make, however, statistics ultimately unreliable.

Table 1

Clinical data of the patients and reviewed cases.

Pat. no.	Sex, age	Deletion size / coordinates	Prenatal				Postnatal											Relative with possibly related clinical phenotype	Ref
			Urinary system	DH	Other anomalies	Amniotic fluid	Urinary system	LBW/Growth delay	Respiratory	Digestive	Cardiovascular	Neurological	Muscular	Bone	Genital	Facial dysmorphism	Other
1.	Fetus#n/a	1.42 Mb34,822,465–36,243,365 (hg19)	HN	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9
2.	Fetusn/a	1.48 Mb34,832,294–36,316,144 (hg19)	Left MCDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	C	13
3.	Fetus#n/a	1.58 Mb34,822,465–36,404,104 (hg19)	bDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9
4.	Fetusn/a	1.58 Mb34,822,465–36,404,104 (hg19)	Right MCDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	C	13
5.	Fetus#n/a	1.59 Mb34,822,456–36,410,720 (hg19)	bHK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14
6.	Fetus#n/a	1.74 Mb31,836,750–33,582,750 (hg17)[34,762,637–36,252,627 (hg19)]	bMDK UTA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
7.	Fetus#17 weeks	1.32 Mb34,851,537–36,168,104(hg19)	UTA	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	Patient B current study
8.	Fetus, male#18 wksbrother of P49	1.75 Mb34,653,178–36,402,867 mat (hg19)	bHK, bHN, UTA (18 wks)MK, HN, UTA (21 wks)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+ C	15
9.	Fetus, female§19 wks	1.39 Mb31,890,483–33,281,801 (hg18)[34,816,370–36,207,688 (hg19)]	bHK (at 19 wks)bhK, MCK (at 25 wks)	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	16
10.	Fetus#22 weeks	1.57 Mb34,815,551–36,383,538 (hg19)	bHK (22 weeks)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17
11.	Fetus, male#22 wkson of P79, brother of P25	n/an/a, pat	bHK, bDK, one cyst	-	+	-	-	-	-	-	-	-	-	-	-	-	-	+ C	7
12.	Fetus#22 wks	1.58 Mb34,822,465–36,404,136 (hg19)	HK, MDK	-	-	-	-	-‘	-	-	-	-	-	-	-	-	-	-	18
13.	Fetus22 wks	1.58 Mb34,822,492–36,404,104 (hg19)	HK, bHN	-	-	-	-	-‘	-	-	-	-	-	-	-	-	-	-	18
14.	Fetus#23 wks	1.60 Mb34,822,465–36,418,529 (hg19)	HK, bDK	-	-	-	-	-‘	-	-	-	-	-	-	-	-	-	-	18
15.	Fetus23 wks	1.94 Mb34,475,679–36,410,720 (hg19)	HK, left MCDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18
16.	Fetus#24 weeks	1.35 Mb34,817,422–36,168,104 (hg19)	MDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Patient A current study
17.	Fetus24 wksoffspring of P80	1.42 Mb34,822,465–36,244,332 (hg19)	HK, MDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+ C	18
18.	Fetus24 wks	1.42 Mb34,822,465–36,243,365 (hg19)	HK	-	-	PHA	-	-	-	-	-	-	-	-	-	-	-	-	18
19.	Fetus24 wks	1.49 Mb34,822,465–36,307,773 (hg19)	left HK, right MCDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18
20.	Fetus#24 wks	1.60 Mb34,822,465–36,418,529 (hg19)	bMCDK, bilateral cystic adenomatoid malformation	-	+	AHA	-	-	-	-	-	-	-	-	-	-	-	-	18
21.	Fetus25 wks	1,49 Mb34,822,465–36,316,144 (hg19)	HK	-	-	PHA	-	-	-	-	-	-	-	-	-	-	-	-	18
22.	Fetus26 wks	1.58 Mb34,822,465–36,404,555 (hg19)	HMDK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18
23.	Fetus, male#32 wks	1.93 Mb34,477,479–36,404,104 (hg19)	bHMDK	-	+	PHA	-	-	-	-	-	-	-	-	-	-	-	-	19
24.	Fetus#32 wks	1.93 Mb34,477,479–36,404,104 (hg19)	bHMDK	-	-	PHA	-	-	-	-	-	-	-	-	-	-	-	-	18
25.	Fetus, female#34 wksdaughter of P79,sister of P11	n/an/a, pat	bHK	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	7
26.	n/a§n/a	1.58 Mb34,822,465–36,404,555 (hg19)	HK	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	9
27.	Male1 m.o.son of P83	n/an/a, mat	-	-	+	OHA	bMCK	+	-	-	-	-	-	-	-	-	-	+ C	7
28.	Female4 m.o.	1.49 Mb34,822,465–36,311,009 (hg19)	HK	+	+	PHA	-	-	+	+	+	-	-	-	-	-	-	-	20
29.	Male4 m.o.	1.43 Mb31,889,297–33,323,037 (hg18)[34,815,184–36,248,924 (hg19)]	MK	-	-	OHA	MK	+	-	-	+	-	-	+	+	-	-	-	2
30.	Male5 m.o.twin of P31	1.59 Mb34,822,465–36,418,529 pat (hg19)	bHKmild renal PCD	+	+	PHA	HMKPCDAF	+	-	-	-	-	-	-	-	-	-	+ C	20
31.	Male5 m.o.twin of P30	1.59 Mb34,822,465–36,418,529 pat (hg19)	bHKmild renal PCD	-	-	-	bHMKAF	+	-	-	-	-	-	-	-	-	-	+ C	20
32.	n/a7 m.o.	1.48 Mb34,822,465, 36,307,773 (hg19)	RPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9
33.	Male7 m.o.son of P76	1.69 Mb31,635,490–33,323,002 mat (hg18)[34,611,377–36,248,889 mat (hg19)]	bMK	-	+	-	bMK	+	-	+	-	-	-	+	-	+	+	+ C	4
34.	Male9 m.o.son of P85	1.60 Mb34,856,085–36,455,391 mat (hg19)	HK	-	-	PHA	MK	+	-	-	-	-	-	-	-	-	-	+ C	21
35.	Male1 y 9 m.o.son of P88	1.38 Mb31,893,783–33,277,865 mat (hg18)[34,819,670–36,203,752 mat (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+ C	12
36.	Female1 y 10 m.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
37.	n/a2 y.o.	1.58 Mb34,822,465–36,404,555 (hg19)	MCK	-	-	-	MDK	+	-	-	-	+	-	-	-	-	-	-	9
38.	Female2 y.o.daughter of P84	n/an/a, mat	-	-	-	PHA	-	+	-	+	-	+	-	-	+	+	+	+ C	7
39.	Male2 yrs 6 m.o.brother of P42	1.40 Mb31,923,035–33,323,544 mat (hg18)[34,848,922–36,249,431 mat (hg19)]	different size kidneys (30 wks)	-	-	-	bHMDK	+	-	-	-	+	-	-	-	-	-	+ C	22
40.	Male3.5 y.o.	1,84 Mb31,550,027–33,399,810 (hg18)[34,525,914–36,307,186 (hg19)]	CK	-	-	-	-	-	-	-		+	-	-	-	-	-	-	23
41.	Male3.8 y.o.	1,50 Mb31,889,664–33,386,049 (hg18)[34,815,551–36,295,000 (hg19)]	HK	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	23
42.	n/a4 y.o.sibling of P39	1.40 Mbn/a pat	HK (33 weeks)	-	-	-	MK(9 mo)	-	-	-	-	+	+	+	-	-	-	+ C	17
43.	n/a4 y.o.	1.70 Mb34,550,633–36,248,889 pat (hg19)	HK (23 weeks)	-	-	-	MK(6 mo)	-	-	-	-	+	-	-	-	-	-	+ C	17
44.	Female4 y.o.twin of P45	1.57 Mb34,815,551–36,383,538 (hg19)	HK	-	-	-	HMCK	-	-	-	-	+	-	-	-	-	-	-	17
45.	Female4 y.o.twin of P44	1.57 Mb34,815,551–36,383,538 (hg19)	HK	-	-	-	HMCK	-	-	-	-	+	-	-	-	-	-	-	17
46.	Female4 y.o.	1.79 Mb34,629,683–36,424,950 pat (hg19)	absent left kidney	-	+	PHA	HMDK	+	-	+	-	+	-	-	-	+	-	+ C	24
47.	Male4 y.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
48.	Male4 y.o.	2.07 Mb31,635,490–33,708,909 (hg18)[34,611,377–36,455,391 (hg19)]	MK	-	-	-	MK /HK	+	-	-	-	+	+	-	+	+	+	-	4
49.	Female5 y.o.◆sister of P8	1.75 Mb34,653,178–36,402,867 mat (hg19)	-	-	-	-	bDK	-	-	-	-	-	-	-	-	-	-	C	15
50.	Male5 yrs. 6 m.o.	1.43 Mb31,889,297–33,323,037 (hg18)[34,815,184–36,248,924 (hg19)]	MDK	-	-	-	MDKAF	+	-	-	-	-	-	+	-	-	-	-	2
51.	Male5 yrs. 8 mo.	1.88 Mb34,437,475–36,243,028 (hg19)	bHK (15 wks)bMK (17 wks)	+	-	-	HMKAF	-	+	+	+	-	-	+	-	+	-	-	25
52.	Female6 y.o.sister of P60,daughter of P89	n/an/a, mat	-	-	-	-	-	-	-	-	-	+	-	-	-	+	-	+ C	7
53.	Male6 y.o.	n/an/a	-	-	-	-	AG	+	+	-	-	+	+	-	-	-	+	-	26
54.	Female7 y.o.sibling of P34	1.40 Mb31,923,035–33,323,544 mat (hg18)[34,848,922–36,249,431 mat (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+ C	22
55.	Male7 y.o.	n/an/a	-	-	-	-	One cyst, partial duplicated collecting system	+	+	+		+		+		+	+	-	7
56.	Male7 y.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
57.	Male7 yrs 5 mo	1.80 Mb34,475,679–36,283,807(hg19)	HN (22 weeks)	-	-	-	-	+	-	-	-	+	-	-	-	+	-	-	Patient C current study
58.	Male8 y 8 m.o.	n/an/a	-	-	+	-	-	+	-	-	+	+	-	-	-	+	-	-	27
59.	Male9 y.o.	1.83 Mb31,543,857–33,371,626 (hg18)[34,519,744–36,335,380 (hg19)]	HK, MCK, PY, HY	-	-	-	moderate renal failure	-	-	+	-	+	-	-	-	-	-	-	23
60.	Female10 y.o.sister of P52,daughter of P89	n/an/a, mat	-	-	-	-	-	+	-	-	-	+	-	-	-	+	-	+ C	7
61.	Male10 y.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
62.	Male10 y.o.son of P82	1.78 Mb34,468,470–36,248,889 mat (hg19)	bHMK	-	-	-	LK	-	-	-	-	+	-	-	-	+	-	+ C	21
63.	Female12 y.o.	n/an/a	-	-	+	-	-	+	-	+	-	+	-	-	-	+	+	+	27
64.	Female12 y.o.	1.73 Mb31,593,883–33,323,002 (hg18)[34,569,770–36,248,889 (hg19)]	bHMK	-	-	-	MK	-	-	-	-	+	-	-	-	-	-	+	4
65.	Male12 y.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
66.	Male12 y.o.	1.43 Mb34,816,255–36,244,358 (hg19)	-	-	-	-	-	-	-	-	-	+	-	-	-	+	-	-	5
67.	Female13 y.o.	1,43 Mb31,889,297–33,323,037 (hg18)[34,815,184–36,248,924 (hg19)]	MK	-	-	-	-	+	-	-	-	+	-	-	-	-	-	+	2
68.	Female14 y.o.	n/an/a	MCK	-	-	PHA	left AG	-	-	-	-	+	-	-	-	-	+	-	7
69.	Male15 y. 8 m.o.	1.42 Mbn/a	-	-	-	-	bMCK	+	-	-	-	+	-	-	-	+	+	-	27
70.	Male17 y.o.	1.89 Mb34,464,879–36,352,140 (hg19)	-	-	-	-	-	+	-	-	+	+	-	+	-	-	+	-	28
71.	Female18 y.o.	1.42 Mbn/a	-	-	-	-	bMCK	-	-	-	-	-	-	-	-	-	O, D	+	27
72.	Female18 y.o.	1.50 Mbn/a	-	-	-	-	MCD	-	-	+	-	+	-	-	-	-	-	-	29
73.	Female19 y.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
74.	Female20 y.o.	1,43 Mb31,889,297–33,323,037 (hg18)[34,815,184–36,248,924 (hg19)]	-	-	-	-	DKAG	-	-	-	-	+	-	-	-	-	+	-	2
75.	Male20 y.o.	1.40 Mbn/a	-	-	-	-	UVJO	-	-	+	-	+	-	-	-	-	D, Mg↓	-	30
76.	Female22 y.o.mother of P33	1.69 Mb31,635,490–33,323,002 (hg18)[34,611,377–36,248,889 (hg19)]	left MCDK	-	-	-	involution of leftMCDK	-	-	-	-	-	-	-	-	-	-	+	4
77.	Male22 y.o.	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
78.	Female26 y.o.	1.58 Mb34,790,209–36,373,398 (hg19)	MCK	-	-	-	-	-	-	+	-	+	-	-	-	-	D	-	31
79.	Male26 y.o.father of P48, P50	n/an/a	-	-	-	-	bHK	+	-	+	-	+	-	+	-	+	O	+ C	7
80.	Female28 y.o.mother of P67	1.42 Mb34,822,465–36,244,332 (hg19)	HK	-	-	-	bMCK	-	-	-	-	-	-	-	-	-	-	+ C	18
81.	Female28 y.o.	1.80 Mbn/a	-	-	-	-	bMCK, AF	+	-	+	-	+	-	-	-	-	-	+	27
82.	Female29 y.o.mother of P24	1.78 Mb34,468,470–36,248,889 (hg19)	bHMK	-	-	-	one cyst	-	-	-	-	+	-	-	-	+	-	+ C	21
83.	Female30 y.o.mother of P56	n/an/a	-	-	-	-	-	-	-	-	-	+	-	-	-	-	D	+ C	7
84.	Female32 y.o.mother of P46	n/an/a	-	-	-	-	bHY, bNP	-	-	+	-	+	-	-	-	-	-	+	7
85.	Female32 y.o.mother of P14	1.59 Mb34,856,085–36,455,391 (hg19)	-	-	-	PHA	bMK	-	-	+	-	-	-	-	-	-	O, D	+ C	21
86.	Female35 y.o.	1.58 Mb34,822,465–36,404,104 (hg19)	-	-	-	-	MCK	-	-	+	-	-	-	-	-	+	+	+ C	32
87.	Female36 y.o.	1.58 Mb34,790,209–36,373,398 (hg19)	-	-	-	-	MCKkidney failure	-	-	+	-	+	-	-	-	+	D	-	31
88.	Female37 y.o.mother of P87	1.38 Mb31,893,783–33,277,865 (hg18)[34,819,670–36,203,752 (hg19)]	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	12
89.	Female38 y.o.mother of P53, P54	n/an/a	-	-	-	-	HY	-	-	-	-	+	-	-	-	-	-	+ C	7
90.	Male43 y.o.	n/an/a	-	-	-	-	HN, UPJO	-	-	+	+	+	-	+	-	-	+Mg↓	-	33
91.	Female45 y.o.	n/an/a	-	-	-	-	a/hypoplasia, AF	-	-	-	+	-	-	+	+	-	O, D	-	27
92.	Male62 y.o.	1,41 Mb34,815,551–36,223,325 (hg19)	-	-	-	-	bMCK	-	-	-	+	+	-	+	-	-	Mg↓, D	+	34
	TOTAL	1.32–2.07 MbSmallest deleted region:34,851,537–36,168,104 (hg19)	56/92 (60.9%)	4/92 (4.3%)	12/92 (13.0%)	14/92 (15.2%)	32/75 (42.7%)	23/75 (30.7%)	4/75 (5.3%)	18/75 (24%)	8/75 (10.7%)	49/75 (65.3%)	3/75 (4%)	11/75 (14.7%)	4/75 (5.3%)	18/75 (24%)	21/75 (28%)	34/75 (45.3%)C: 28/75 (37.3%)

AF – affected renal function; AG – agenesia; AHA – anhydramnios; b – bilateral; C – genetically confirmed; D – diabetes; DD – developmental delay; DF – dysmorphic features; DH – diaphragmatic hernia; DK - dysplastic kidney; DM – diabetes mellitus; HK – hyperechogenic kidney; HMK – hyperechogenic multicystic kidney; HMDK – hyperechogenic multicystic dysplastic kidney; HMK – hyperechogenic multicystic kidney; HN – hydronephrosis; HY – renal hypoplasia; ID – intellectual disability; LBW – low birth weight; LK – lobulated kidney; LOFC – low occipitofrontal circumference; MCK – multicystic kidney; MDK - multicystic dysplastic kidney; NP – nephropathy; NT - nuchal fold thickness; O – ocular anomalies; OHA – oligohydramnios; PCD – pelvicalyceal dilatation; PD – pelvic dilatation; PHA – polyhydramnios; PY – pyelectasis; RPS – renal pelvis separation; UPJO – ureteropelvic junction obstruction; UTA – urinary tract anomalies; UVJO - ureterovesical junction obstruction;

-pregnancy terminated;

- died after birth;

- death at a later age.

Among the reviewed patients, 42.7% had kidney anomalies, at least 30.7% exhibited some degree of developmental delay, and 65.3% had neuropsychiatric features such as autism, intellectual disability of variable severity, or attention deficit. Thus, the neuropsychiatric phenotypes appear to be more frequent among the patients with 17q12 microdeletion than renal disorder. Among other phenotypes described in these patients were fetal diaphragmatic hernia (4.3%) and amniotic fluid anomalies (polyhydramnios 12%; oligohydramnios 2.1%; anhydramnios 1.1%) in prenatal cases, and in postnatal cases, digestive tract anomalies, particularly related to liver and pancreas (24%), cardiovascular anomalies (10.7%), skeletal anomalies (14.7%), facial dysmorphisms (24%). Ocular anomalies, diabetes, and hypomagnesemia were also described, albeit rarely. The broad spectrum of observed phenotypes emphasizes, once more, the high variability of this syndrome, adding to a 34.4% incomplete penetrance estimated in the case of this deletion [36].

For 45.3% of the cases, family history included potentially related phenotypes, though with only 37.3% being genetically confirmed. 10 out of 92 patients inherited the microdeletion from either a mildly affected or an affected parent, while 4 out of 92 inherited it from an asymptomatic parent. Although dedicated databases such as DECIPHER and CNV Morbidity Map of Developmental Delay list large numbers of cases with this genetic aberration, two deletions are also found in the Control section of the last morbidity map (Figure 1), proving, in accordance with Mefford et al. (2007) [1], that asymptomatic carriers may not be uncommon. Differences in deletion size (or other genetic modifiers) may also account for part of the observed phenotypic variation, although almost identical deletions (including in twins) may lead to variable phenotypes.

Figure 1

Graphical representation of the reported and reviewed deletions in UCSC browser. Patient ID is indicated according to Table 1. The arrows point the patients described in the current study.

The third patient had ASD as a main feature, in association with mild developmental delay, dysmorphic features and prenatal hydronephrosis. ASD has been previously reported in patients with 17q12 deletion, e.g., Vasileiou et al. [2019] [27] described 2 cases and Loirat et al. (2010) [23] reported 3 unrelated boys with de novo 17q12 deletion, with ASD and kidney problems, hypothesizing that autistic behavior may be due to HNF1B deletion. Yet, Clissold et al. (2016) [37] found ASD as a main feature of this syndrome, alone or in association with learning difficulties and/or attention deficit hyperactivity disorder (ADHD). This was not, however, found in subjects with HNF1B gene mutation. Moreno-de-Luca et al. (2010) [12] reported on 6 boys out of 18 patients with 17q12 deletion, who presented ASD in association with other manifestations (dysmorphic features, kidney problems, macrocephaly, intellectual disability). This deletion was also found in patients with schizophrenia. The authors concluded that 17q12 deletion is associated with a high risk for ASD and schizophrenia, and that at least one out of the 15 genes included in this region is important for normal brain development. It has also been noted that the degree of severity of the neuropsychological phenotype is lower in patients referred for kidney anomalies, than in patients with only neurological symptoms. Laliève et al. (2019) [38] found that 87.3% of the 119 patients carrying a HNF1B (or larger) deletion, attended mainstream schooling, though Laffargue et al. (2015) [8] report that only approx. 60% of the children enrolled in their study had a normal progression through school. Thus, 17q12 microdeletion does not systematically involve neuropsychological anomalies. Yet, a tendency toward a lower IQ and a higher risk of neuropsychological disorders for the carriers of the microdeletion, as compared with normal population was noted.

Kaman et al. (2019) reported a 17q12 deletion patient with atopic dermatitis and allergy; however, while an association of these clinical manifestations with this genetic defect is possible, the presence of a different genetic anomaly was not excluded [26].

In conclusion, we bring further evidence for the genetic and morpho-physiological complexity of the 17q12 deletion syndrome, and report a novel, atypical clinical phenotype (patient B), with megabladder, single umbilical artery and choroid plexus cyst, not yet described in fetuses with 17q12 deletion. However, whole gene deletion of HNF1B has been previously associated with megabladder in a patient with prune belly phenotype [39], a disorder with a partially overlapping clinical presentation with 17q12 deletion syndrome. Our first case strongly suggests that genetic testing should be considered for isolated or unilateral multicystic dysplastic kidneys, though current fetal medicine guidelines recommend invasive investigations only in bilateral forms or when other organs are involved (The FMF Foundation [40]). Nonetheless, 17q12 microdeletion should always be considered in patients with ASD, especially in association with developmental delay and kidney problems. 17q12 microdeletion syndrome is challenging due to the wide clinical spectrum and the high variability of this disorder even within the same family. In addition to the uncertainty regarding long-term postnatal outcome, more patients and more longitudinal studies should be considered in order to reach a higher degree of accuracy in the counselling of prospective parents.